**Question:** Drug acting tyrosine kinase receptor is

A. Angiogenesis inhibitors (e.g., Bevacizumab)
B. Immune checkpoint inhibitors (e.g., Pembrolizumab)
C. Tyrosine kinase inhibitors (e.g., Imatinib)
D. Prostaglandin synthetase inhibitors (e.g., Indomethacin)

Correct Answer: C. Tyrosine kinase inhibitors (e.g., Imatinib)

**Core Concept:**
Tyrosine kinase receptors are a class of cell surface receptors that play a crucial role in various physiological processes, including cell growth, differentiation, and survival. They are involved in signaling pathways that involve the phosphorylation of specific tyrosine residues on intracellular proteins. Drugs acting on tyrosine kinase receptors are known as tyrosine kinase inhibitors (TKIs).

**Why the Correct Answer is Right:**
Tyrosine kinase inhibitors (TKIs) are drugs that specifically target and inhibit the activity of tyrosine kinases, which are enzymes that play a significant role in cell signaling pathways. Imatinib (Gleevec) is a well-known example of a TKI that has revolutionized the treatment of certain types of cancers, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

**Why Each Wrong Option is Incorrect:**
A. Angiogenesis inhibitors like Bevacizumab (Avastin) target the VEGFR (Vascular Endothelial Growth Factor Receptor) tyrosine kinase, which is involved in regulating blood vessel formation (angiogenesis). While they do interact with tyrosine kinase receptors, they are not specific for tyrosine kinases involved in cell signaling pathways.
B. Immune checkpoint inhibitors like Pembrolizumab target immune system proteins to enhance immune response against cancer cells. Although they also interact with tyrosine kinase receptors, they are designed to modulate the immune system rather than directly inhibit cell signaling pathways.
D. Prostaglandin synthetase inhibitors, such as Indomethacin, target the enzyme cyclooxygenase (COX) in the synthesis of prostaglandins from arachidonic acid. These drugs primarily affect the inflammatory process, not cell signaling pathways involving tyrosine kinases.

**Clinical Pearl:**
Understanding the pharmacology of tyrosine kinase inhibitors is essential for treating malignancies and other conditions involving abnormal cell signaling. Tyrosine kinase inhibitors are a class of drugs with a selective mechanism of action, targeting specific tyrosine kinases involved in cell signaling pathways. This distinguishes them from other drugs targeting angiogenesis (e.g., Bevacizumab) or immune checkpoints (e.g., Pembrolizumab).